Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor 
antagonist currently undergoing clinical trials for migraine 
(http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being 
studied in phase III clinical trials.